 
- 积分
- 1500
- 威望
- 354
- 金钱
- 3
- 阅读权限
- 70
- 在线时间
- 117 小时
|
In January 2021
In January 2021, Pfizer announced that its Oxoidplatform technology successfully passed the Emergency Use Authorization (EMA) review of the U.S. Food and Drug Administration (FDA) and planned to launch a new crown vaccine at the end of 2021. In May 2021, the inactivated new coronavirus vaccine (BNT162b2) jointly developed by Pfizer and German BioNTech was successful in the Phase 3 trial and became the world's first new crown vaccine to obtain conditional marketing authorization from the FDA. |
|